How Autonomous Labs are Revolutionizing Drug Discovery with Michelle Lee - Founder & CEO of Medra AI

Unlock the future of drug discovery with AI-powered robots that could revolutionize science as we know it! Joining us at Catalio Conversations is Michelle Lee, CEO of Medra AI, where she reveals how combining AI & robotics is creating the world's most advanced autonomous labs – think 100 robots working overnight to accelerate cures for disease! Michelle’s journey from chemical engineering and AI research to leading Medra’s groundbreaking "physical AI scientists" offers a blueprint for turning science fiction into reality. Looking ahead, Michelle envisions a world where entire drug pipelines are fully autonomous, enabling any scientist to create life-changing medicines. Perfect for life sciences leaders, AI enthusiasts, as well as tech-curious or business-curious viewers eager to see what’s next, this episode reveals the seismic shifts that will define the next decade of scientific discovery. Don’t miss this glimpse into the autonomous labs of tomorrow – because the next genetic breakthrough could come from a robot, not a human. Timestamped summary: 0:03 - Introduction: Welcome to Catalio Conversations 0:31 - Michelle Lee's Journey: Discussing the realization of the need for AI and robotics in biology. 1:00 - Alpha Fold Inspiration: The impact of Alpha Fold 2 on Michelle's vision. 1:25 - Data Generation with Robotics: How robots can scale up experimentation. 1:53 - Cultural Values at Medra: Insights from Michelle's diverse experiences. 2:21 - Medra's Interdisciplinary Approach: Combining engineering, AI, and biology. 3:13 - Physical AI Scientists: Differentiating from traditional lab automation. 4:08 - Challenges in Data Generation: The need for more and better data. 5:00 - Robotics in Experimentation: Solving data quantity and quality issues. 5:54 - Real Lab Stories: How Medra improved data generation for a client. 7:09 - Overcoming Skepticism: Transitioning from industrial to physical AI. 8:00 - Early Challenges at Medra: Learning from initial business strategies. 9:25 - Partnership Model: Medra's collaborative approach with clients. 10:17 - Recognition by Genentech: Being named a partner in AI strategy. 11:05 - Building Trust: Importance of fast communication and transparency. 11:56 - Future of Labs: Vision for autonomous labs and their impact. 12:43 - Empowering Scientists: Enabling scientists to start their own companies. 13:10 - Quick Fire Questions: Myths and future bets in AI and life sciences. 14:05 - Conclusion: Closing remarks and invitation to subscribe. About Catalio Conversations: Welcome to Catalio Conversations! We spotlight founders & CEOs across innovative healthcare, AI & life sciences, who are building the next generation of disruptors in the space – from drug discovery and autonomous labs to clinical intelligence & beyond. The future starts here. Resources & Links: Medra AI Lab -    • Introducing Medra Lab 001   Medra AI Official Website - https://www.medra.ai/ Compliance disclaimer: Martha Petrocheilos is employed at Catalio Capital Management, LP. All views expressed here by Catalio employees and guests are solely their opinions and do not reflect the opinions of Catalio Capital Management, LP. You should not treat any opinions expressed as specific endorsement to make a particular investment. Any past performance discussed is not indicative of future results and investment in a fund entails a high degree of risk, including the risk of loss. References to any securities are for informational purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services.